Bank Of America Corp Outlook Therapeutics, Inc. Transaction History

Bank Of America Corp

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2023 Feb 14, 2024	BUY	$0.22 - $0.66 $33,126 - $99,380	150,577 Added 230.0%	216,044 $84,000
Q2 2023 Aug 14, 2023	SELL	$1.02 - $1.89 $63,250 - $117,198	-62,010 Reduced 48.64%	65,467 $113,000
Q1 2023 May 12, 2023	SELL	$1.0 - $1.35 $20,907 - $28,224	-20,907 Reduced 14.09%	127,477 $138,000
Q4 2022 Feb 10, 2023	BUY	$0.87 - $1.33 $48,162 - $73,627	55,359 Added 59.51%	148,384 $160,000
Q3 2022 Nov 14, 2022	BUY	$1.02 - $1.26 $899 - $1,111	882 Added 0.96%	93,025 $113,000
Q2 2022 Aug 12, 2022	SELL	$0.91 - $2.01 $24,790 - $54,756	-27,242 Reduced 22.82%	92,143 $93,000
Q1 2022 May 16, 2022	SELL	$1.22 - $2.03 $2,260 - $3,761	-1,853 Reduced 1.53%	119,385 $212,000
Q4 2021 Feb 08, 2022	BUY	$1.27 - $2.23 $147,816 - $259,551	116,391 Added 2401.3%	121,238 $165,000
Q3 2021 Nov 15, 2021	BUY	$2.12 - $2.76 $10,186 - $13,261	4,805 Added 11440.48%	4,847 $11,000
Q2 2021 Sep 13, 2021	BUY	$1.78 - $2.76 $74 - $115	42 New	42 $0

31.5K

Ticker OTLK
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 226,144,992
Market Cap $1.17B
Description
Outlook Therapeutics, Inc., a late clinical-stage biopharmaceutical company, focuses on developing and commercializing monoclonal antibodies for various ophthalmic indications. Its lead product candidate is ONS-5010, an ophthalmic formulation of bevacizumab product candidate that is in Phase-III clinical trial for the treatment of wet age-relate...

Get notified when there are updates to the investment portfolio of Bank Of America Corp , based on Form 13F filings with the SEC.

Stay updated on Bank Of America Corp with notifications on news.